ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)

NCT06128395 | Completed

• 1 other identifier: 3384
• Study Type: observational
• Target: 1,207
• Locations: 1 country
• Sites: 1

Brief Summary

The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific population, the use of low dose aspirin might reduce the risk of preterm birth in pregnant women with singleton pregnancy. In June 2022, clinique ovo started implementing the use of Aspirin 162 mg instead of 81 mg in the frozen embryo transfer cycles based on recent study outcomes. The use of Aspirin 162 mg might have additional benefits on the embryo transfer outcomes by decreasing the miscarriage. Moreover this can be continued until late in pregnancy without adverse effects.

Conditions

Fertility Disorders

Outcome Measures

Primary Outcomes (1)

• Compare clinical pregnancy rate between patients prescribed Aspirin 81 mg vs Aspirin 162 mg

  clinical pregnancy is the presence of fetal heartbeat at the viability ultrasound

  Time Frame: 6 to 8 weeks after Frozen Embryo Transfer

Study Arms (2)

Aspirin 81 mg for Frozen Embryo Transfer (FET)

Subjects were prescribed Aspirin 81 mg to be started on the third day of their menstrual cycle in preparation for their FET.

Other: Frozen embryo transfer

Aspirin 162 mg for Frozen Embryo Transfer (FET)

Subjects were prescribed Aspirin 162 mg to be started on the third day of their menstrual cycle in preparation for their FET

Other: Frozen embryo transfer

Interventions

Frozen embryo transfer OTHER

A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Aspirin 162 mg for Frozen Embryo Transfer (FET); Aspirin 81 mg for Frozen Embryo Transfer (FET)

Eligibility Criteria

• Age: Up to 40 Years
• Gender Eligibility Details: Women able to have an embryo transfered in their uterus
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

FET Data spreadsheet from January 2022 to December 2022

You may qualify if:

• Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer
• Age \< 40 years old
• Embryo transfer cycle done at clinique ovo

You may not qualify if:

• Egg or embryo recipient
• History of recurrent miscarriages, defined as ≥ 3 consecutive losses
• Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness
• Uterine factor infertility
• Abnormal hormonal profiles
• Stimulated embryo transfer cycles
• History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts

Sponsors & Collaborators

• Clinique Ovo: lead

Study Sites (1)

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

Location

Study Officials

• Wael Jamal, MD

  Clinique Ovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2023
• First Posted: November 13, 2023
• Study Start: November 1, 2023
• Primary Completion: August 30, 2024
• Study Completion: September 18, 2024
• Last Updated: December 9, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)